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Abstract
The introduction of erythropoiesis-stimulating agents
(ESAs) into everyday clinical practice has greatly improved
the care of patients with chronic kidney disease. ESAs have
reduced the need for blood transfusions, improved survival,
decreased cardiovascular complications and enhanced pa-
tient quality of life. The longer acting ESA, darbepoetin alfa
(Aranesp R©), which can be administered less frequently than
traditional ESAs, provides further benefits to both patients
and healthcare professionals relative to the epoetins. Clin-
ical studies have shown that darbepoetin alfa administered
once every 2 weeks or once every month allows enhanced
convenience and cost savings with no compromise in effi-
cacy, while maintaining patients within target haemoglobin
ranges.
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Introduction
Anaemia in patients with chronic kidney disease (CKD) is
a common complication that has been associated with poor
outcomes such as cardiovascular complications and mor-
tality [1,2]. Erythropoiesis-stimulating agents (ESAs) have
been available for almost two decades and remain the cen-
tral strategy for the treatment of anaemia in patients with
CKD. The use of ESAs in the management of renal anaemia
has been shown to improve survival, reduce cardiovascu-
lar morbidity and enhance quality of life [3–7]. In the last
2 years however, new studies have called into question the
safety of treating patients to higher haemoglobin (Hb) levels
after patients treated to Hb targets>13 dL had a greater risk
of cardiovascular events (CREATE [8], CHOIR [9] and an
accompanying meta-analysis [10]). Subsequently prescrib-
ing information for ESAs has been updated to recommend
a target Hb range of 10–12 g/dL for all patients [11–14]. A
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recently published secondary analysis of the CHOIR study
[15] suggests that high doses of epoetin alfa, rather than
high Hb targets, were the culprit for the increased risk of
poor outcomes. The ongoing randomized Trial to Reduce
cardiovascular Events with Aranesp Therapy (TREAT) is
anticipated to add further clarity to this issue [16,17].
Thus, anaemia management is rapidly evolving, as new
trial designs and an increasing number of treatment op-
tions continue to advance the understanding of Hb control
in patients with CKD. Clearly, maintaining patients within
target Hb ranges is more important than ever, and the abil-
ity of ESAs to contribute to Hb control will be under new
scrutiny. Darbepoetin alfa, the first ESA to offer extended
dosing intervals over the erythropoietin molecules, epoet-
ins alfa and beta, has played an important role in enhancing
anaemia management. In this review, we will explore the
clinical and economic considerations for the use of darbe-
poetin alfa in the treatment of anaemia in CKD patients.
Dosing frequency
Currently approved dosing intervals for ESAs in the treat-
ment of renal anaemia are shown in Table 1 [11–14,18–20].
Darbepoetin alfa is indicated for less frequent administra-
tion than the epoetins/epoetin biosimilars. Table 2a summa-
rizes the evidence from clinical studies supporting the effi-
cacy and safety of darbepoetin alfa administered once every
2 weeks (Q2W) and once every month (QM) in patients with
CKD not on dialysis [21–28]. In Table 2b, studies support-
ing darbepoetin alfa once weekly (QW) and Q2W regimens
in patients on dialysis are summarized [29–33]. Patients re-
ceiving epoetin twice weekly (BIW) or three times weekly
(TIW) can be converted to darbepoetin alfa administered
QW, while those receiving epoetin QW can be converted
to darbepoetin alfa administered Q2W [12]. A darbepoetin
alfa QM dosing interval is recommended in patients not on
dialysis who are already stable on darbepoetin alfa Q2W
[12].
Less frequent dosing intervals, Q2W and QM, have also
been approved for pegylated epoetin beta based on recently
reported studies in patients not on dialysis and on dialysis
[34–37].
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Table 1. Approved European Union dosing intervals with ESAs for CKD patients
3×/2× weekly Once weekly Every 2 weeks Once monthly
Epoetin alfa (Eprex R©) [11]  – – –
Epoetin alfa biosimilars (Abseamed R©, Binocrit R© or Epoetin
alfa HEXAL R©) [18–20]
i.v. only i.v. onlya – –
Epoetin beta (NeoRecormon R©) [13]  s.c. only s.c. only –
Pegylated epoetin beta (MIRCERA R©) [14] – – b c
Darbepoetin alfa (Aranesp R©) [12] –  d s.c. onlye
aFor maintenance only.
bFor correction only.
cIn pretreated patients only.
dFor maintenance in haemodialysis patients and correction in patients not on dialysis (s.c.).
eFor maintenance in patients not on dialysis (s.c.).
i.v., intravenous; s.c., subcutaneous.
Route of administration
The preferred route of administration for ESAs to CKD pa-
tients who are not on dialysis is via the subcutaneous (s.c.)
route because of a lack of readily available intravenous (i.v.)
access [6]. However, it is worth noting that there have been
fewer reported incidences of pure red cell aplasia following
administration of epoetin alfa via the i.v. route than via the
s.c. route. For patients undergoing haemodialysis, the Euro-
pean Best Practice Guidelines (EBPG) for the management
of anaemia in patients with CKD recommend that the i.v.
route may be preferable for comfort and convenience, but
acknowledge that this route can increase the dose require-
ment for epoetin alfa [6]. As shown by Kaufmann et al.
[38] in 208 haemodialysis patients, the mean weekly epo-
etin alfa dose was 32% lower when administered by the s.c.
route compared to the i.v. route [95.1 (±75.0) versus 140.3
(±88.5) IU/kg/week; P < 0.001].
In contrast to epoetin, darbepoetin alfa has similar dose
requirements for both the s.c. and i.v. routes [31,39]. In a
study by Vanrenterghem et al. [31], 522 dialysis patients
who were stable on either s.c. or i.v. recombinant human
erythropoietin (rHuEPO) therapy were randomized to either
continue their existing treatment (n = 175) or receive an
equivalent dose of darbepoetin alfa administered via the
same route, but at a reduced dose frequency (n = 347).
While darbepoetin alfa dose requirements were similar for
the s.c. and i.v. routes, rHuEPO dose requirements were
22% lower for the s.c. versus the i.v. route. The equivalence
of s.c and i.v. dose requirements for darbepoetin alfa offers
greater simplicity of anaemia management for physicians
relative to the epoetins since a change in administration
route is less likely to necessitate dose adjustment.
Haemoglobin control
As noted above, the ability to maintain patients within tar-
get Hb ranges is of increasing interest due to concerns over
a possible negative impact of high Hb levels and the well-
documented negative effects of low Hb levels. As shown
in Table 2a, studies of extended dosing regimens with dar-
bepoetin alfa in CKD patients not on dialysis have shown
maintenance of Hb within target range in a high propor-
Fig. 1. Patients achieving Hb>11 g/dL after switching from recombinant
human erythropoietin BIW or TIW weekly to once weekly dosing with
darbepoetin alfa [40].
tion of patients (79–96%). High proportions of patients on
dialysis also maintained Hb within the target range while
receiving darbepoetin alfa at extended dosing intervals. As
shown in Table 2b, in a study by Mann et al., 85% of patients
treated with darbepoetin Q2W (n = 1101) maintained Hb
in the target range [33]; similar proportions were observed
in recent smaller studies as detailed below.
In a study by Carrera et al. [32], 105 haemodialysis pa-
tients stable on darbepoetin alfa QW were switched to dar-
bepoetin alfa Q2W. The dose was titrated to maintain patient
Hb levels between 11 and 13 g/dL. During QW dosing, 65%
of patients maintained Hb levels between these values and
during Q2W dosing, 81% of patients maintained Hb levels
within the target range (Table 2b).
In a study by Rutkowski et al. [40], haemodialysis pa-
tients stable on BIW or TIW epoetin, administered s.c. or
i.v., were switched to i.v. darbepoetin alfa administered QW
for 24 weeks. The dose of darbepoetin alfa was adjusted
to maintain patient Hb in the range 11–13 g/dL. Over-
all mean Hb concentrations (measured during weeks 20–
24) increased following the switch to darbepoetin alfa by
0.7 g/dL and up to 23% more patients achieved a Hb con-
centration >11 g/dL (Figure 1).
Conversely, in a study by Biggar et al. [41], 90 haemodial-
ysis patients were switched from darbepoetin alfa to epo-
etin beta treatment. Prior to the switch, the mean Hb con-
centration was 11.4 (±1.0) g/dL and the mean weekly
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Table 2. Studies of darbepoetin alfa administered at extended dosing intervals in CKD patients (a) not on dialysis and (b) receiving dialysis
Panel a
Studies of CKD
patients not on
dialysis
Number of
patients
Study design Treatment + evaluation period Hb target (g/dL) Outcome
Hertel et al. [21] 524 rHuEPO QW → DA Q2W Up to 52 weeks (evaluation weeks 20–32) ≤12 Mean (SD) baseline Hb (g/dL) = 11.2 (1.27)
Multicentre Mean (SD) evaluation Hb (g/dL) = 11.4
(0.04)
Hertel et al. [22] 911 No previous ESA → DA Q2W Up to 52 weeks (evaluation weeks 20–32) ≤12 Mean (SD) baseline Hb (g/dL) = 9.9 (1.0)
Multicentre LSM evaluation Hb (g/dL) = 11.54 [95% CI,
11.47–11.61]
Toto et al. [23] 608 No previous ESA → DA Q2W Up to 24 weeks 11–13 Patients in Hb target range: 96% [95% CI,
94–98]Multicentre, open label
Ling et al. [24] 97 DA Q2W → DA QM 29 weeks (evaluation weeks 21–29) 10–12 Patients in Hb target range: 79% [95% CI,
71–87]Multicentre, open label
Agarwal et al. [25] 98 DA Q2W → DA QM 29 weeks (evaluation weeks 21–29) 10–12 Patients in Hb target range, by age:
Multicentre, open label <65 years: 80% [95% CI, 68–92]
≥65 years: 79% [95% CI, 68–90]
≥75 years: 80% [95% CI, 64–96]
Agarwal et al. [26] 152 DA Q2W → DA QM
Multicentre, open-label
28 weeks (evaluation weeks 25–33) 11–13 Mean Hb ≥11.0 g/dL in 76% [95% CI,
68–83] of patients receiving at least
one dose of DA
Mean Hb>11.0 g/dL in 85% [95% CI,
78–91] of patients completing the study
Hoggard et al. [27] 442 EA Q1W/Q2W → DA QM (then
preference at week 21)
Multicentre, open-label
28 weeks (assessed week 21 for
preference)
10–12 86% [95% CI, 79–91] of patients previously
receiving EA Q1W preferred DA QM at
week 21
Overall (regardless of previous EA dosing
frequency), 88% [95% CI, 84–91] of
patients preferred DA QM at week 21
Disney et al. [28] 66 Q2W → DA QM
Multicentre, open-label
28 weeks (evaluation weeks 21–33) 10–13 83% [95% CI, 74–92] of patients had a mean
Hb ≥10 g/dL)
(Continued)
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Table 2. Continued
Panel b
Studies of CKD patients
receiving dialysis
Number of
patients
Study design Treatment + evaluation period Hb target (g/dL) Outcome
Martinez Castelao et al.
[29]
826 rHuEPO BIW/TIW or QW →
DA QW or Q2W, respectively
24 weeks (evaluation weeks 21–24) 10–13 Mean change in Hb: −0.09 g/dL [95% CI,
−0.2 to 0.0]
Multicentre
Del Vecchio et al. [30] 950 rHuEPO BIW/TIW or QW →
DA QW or Q2W, respectively
24 weeks (evaluation weeks 21–24) 10–13 Mean change in Hb: −0.10 g/dL [95% CI,
−0.18 to −0.02]
Vanrenterghem et al.
[31]
522 rHuEPO BIW/TIW or QW →
DA QW or Q2W, respectively
versus continued rHuEPO
52 weeks (evaluation weeks 25–32) 9–13 (and within −1.0
and +1.5 of baseline)
Mean (SE) change in Hb: DA group: −0.03
(0.11) g/dL
Open label rHuEPO group: −0.06 (0.13) g/dL
Carrera et al. [32] 105 DA QW → DA Q2W
Single centre, open label
12 months (switch after 6 months) 11–13 Mean (SD) Hb (g/dL): Baseline: 11.75 (1.66)
6 months: 11.46 (1.6)
12 months: 11.54 (1.6)
During QW dosing: 65% of patients
maintained Hb levels within the target
range
During Q2W dosing: 81% of patients
maintained Hb levels within the target
range
Mann et al. [33] 1101 rHuEPO QW → DA Q2W
Multicentre pooled analysis of eight
randomized trials
24 weeks (evaluation weeks 21–24) 10–13 Mean (SD) Hb 11.53 (0.77) g/dL at baseline
and 11.35 (1.04) g/dL at evaluation [mean
change of −0.27 g/dL (95% CI, −0.2 to
0.34)]
85% of patients maintained Hb levels within
the target range
BIW, twice per week; CI, confidence interval; CKD, chronic kidney disease; DA, darbepoetin alfa; EA, epoetin alfa; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; LSM, least squares mean;
QM, every month; Q2W, every 2 weeks; QW, every week; rHuEPO, recombinant human erythropoietin (epoetin alfa or epoetin beta); SD, standard deviation; SE, standard error; TIW, three times per week.
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darbepoetin alfa dose was 4335 (±3217) IU/week (using
the recommended European initial equimolar dose con-
version factor, 1 μg darbepoetin alfa converted to 200 IU
epoetin beta) [12]. After the switch to epoetin beta, the
mean Hb concentration was 11.1 (±0.9) g/dL and the mean
weekly dose of epoetin beta had been increased by 13%
to 4885 (±3077) IU/week. Furthermore, while 71% of the
patients had a mean Hb concentration ≥11 g/dL during dar-
bepoetin alfa treatment, following the switch to epoetin beta
this figure decreased to 50%. Thus, darbepoetin alfa ther-
apy demonstrated enhanced efficacy and a reduced dosing
requirement.
As shown in these two studies, and also noted in the
EBPG [6], an increased proportion of patients achieve target
Hb levels after switching to darbepoetin alfa from epoetin.
Dosing efficiency
One of the principal benefits to be derived from the switch
from older ESAs (epoetin alfa or epoetin beta) to darbepo-
etin alfa is the reduction in dose. Dose savings have been
demonstrated in a number of clinical trials on switching to
darbepoetin alfa QW or Q2W (Table 3) [29,39,42–48].
Tolman and colleagues studied the effects of converting
an unselected, iron-replete population of dialysis patients,
stable on s.c. epoetin beta TIW therapy, to s.c. epoetin beta
QW or darbepoetin alfa QW, with the aid of a computer-
ized decision-support system for anaemia management [42]
(Table 3). Dose conversions were made using the 200:1
rule, as recommended by the Aranesp R© European label,
which states that the initial weekly dose of darbepoetin alfa
(μg/week) can be determined by dividing the total weekly
dose of rHuEPO (IU/week) by 200 [12]. While QW dos-
ing with either epoetin beta or darbepoetin alfa provided
adequate control of patient Hb, switching to darbepoetin
alfa QW allowed a 20% dose reduction compared with a
24% increase in dose among the patients switched to epo-
etin beta QW (Figure 2). Following the switch, the anaemia
management system continued to analyse Hb data each
month, acting as a Hb ‘clamp’, fixing population Hb out-
comes to a predictable distribution and advising on dose
adjustments required to maintain mean Hb in the range 11–
12 g/dL. A per-protocol analysis of patients completing the
study showed similar Hb outcomes in patients switching to
QW epoetin beta or QW darbepoetin alfa, both at random-
ization and at study end (Figure 2). However, in patients
switching to darbepoetin alfa QW therapy, a significant
reduction in mean dose was recorded during the course
of the study (from 0.59 μg/kg/week to 0.46 μg/kg/week;
P = 0.002), compared to a significant increase in mean
dose (from 107.5 to 133.2 IU/kg/week; P = 0.002) in
patients switching to QW epoetin beta (Figure 2). Strik-
ingly, the mean dose of epoetin beta (133 IU/kg/week) at 9
months was 44% higher than the mean darbepoetin alfa dose
(92 IU/kg/week).
Other studies have also demonstrated varying degrees
of dose saving after switching from rHuEPO to darbe-
poetin alfa QW [43–45] (Table 3). Results from a recent
meta-analysis, including the studies by Molina et al. [43],
Nissensen et al. [45] and Tolman et al. [42], showed dar-
Fig. 2. Mean haemoglobin [95% confidence interval (CI)] (A) and mean
dose (95% CI) levels (B) after switching from epoetin beta three times
weekly to once weekly dosing with either darbepoetin alfa or epoetin beta
[42].
bepoetin alfa to be more dose efficient when compared to
rHuEPO (epoetin alfa or epoetin beta) [49]. The analysis
included 250 patients on darbepoetin alfa and 372 patients
receiving rHuEPO. Dose efficiency of darbepoetin alfa rel-
ative to rHuEPO was calculated to be 32% (P < 0.0001)
for the combined studies.
The EFIXNES study similarly demonstrated increased
dose efficiency following a switch from rHuEPO to dar-
bepoetin alfa at extended dosing intervals [46] (Table 3).
Haemodialysis patients who were stable on s.c. or i.v.
rHuEPO, with mean Hb concentrations in the range 10.8–
13.0 g/dL, were switched to i.v. darbepoetin alfa (those on
rHuEPO TIW or BIW were switched to darbepoetin QW,
while those on rHuEPO QW were switched to darbepoetin
alfa Q2W). The primary endpoint, the dose of darbepoetin
alfa required to maintain Hb levels within ±1 g/dL of the
baseline value, was assessed over a 4-week evaluation pe-
riod. Hb remained stable following the switch from rHuEPO
QW to darbepoetin alfa Q2W, and there was a 25% overall
dose reduction, with the greatest dose savings occurring
in patients on higher initial doses. For example, while pa-
tients whose baseline rHuEPO dose was <3000 IU/week
had an 8% decrease in dose upon switching to darbepoetin
alfa therapy, those with a baseline dose of 7000–10 000 IU/
week had a 37% dose reduction.
Other studies have also demonstrated varying degrees of
dose saving after switching from rHuEPO to darbepoetin
alfa QW or Q2W [29,39,47,48] (Table 3).
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Table 3. Dose savings on switching from epoetin alfa or epeotin beta BIW or TIW to darbepoetin alfa QW or Q2W
Study Number of
patients
Study design Treatment +
evaluation period
Hb target range (g/dL) Outcome
Tolman et al. [42] 217 EB TIW → DA QW
versus EB TIW →
EB QW
9 months 11–12 Change in mean dose on
conversion to DA: −20%
(0.59 to 0.46 μg/kg/week)
Single centre, open
label
Change in mean dose on
conversion to EB QW:
+24% (107 to 133
IU/kg/week)
Molina et al. [43] 112 rHuEPO s.c. →
rHuEPO i.v. versus
rHuEPO s.c. → DA
QW s.c. or i.v.
24 weeks (evaluation
at weeks 8, 16 and
24)
11–13 DA group: 25% decrease in
REI by week 24
rHuEPO group: 39% increase
in REI by week 24
Ho¨rl et al. [44] 250 rHuEPO BIW/TIW
→ DA QW
24 weeks (evaluation
weeks 21–24)
10–13 Change in mean dose on
conversion to DA: −13.3%
[36.7 (95% CI 33.9–39.7) to
31.8 μg/week (95% CI
28.7–35.2)]
Nissenson et al. [45] 507 rHuEPO TIW → DA
QW versus
continued rHuEPO
TIW
28 weeks (evaluation
weeks 21–28)
9–13 Change in mean (SD) dose on
conversion to DA: Decrease
from 63.18 (49.27) to 54.18
(47.56) μg/week
Multicentre,
double-blind
Change in mean (SD) dose with
continued rHuEPO: increase
from 12 706 (10 349) to 13
639 (12 805) U/week
Bock et al. [46] 132 rHuEPO BIW/TIW or
QW → DA QW or
Q2W, respectively
24 weeks (evaluation
weeks 21–24)
Within ± 1 of baseline levels
(10.8–13)
Change in mean DA dose:
−25% (34.7 ± 2.1 to 26.0 ±
1.8 μg; P < 0.0001)
Multicentre,
open-label
Locatelli et al. [39] 343 rHuEPO BIW/TIW or
QW → DA QW or
Q2W, respectively
24 weeks (evaluation
weeks 21–24)
10–13 Change in mean DA dose:
i.v. group: 25.2 to 21.5 μg/
week; P = 0.004
Multicentre, open
label
s.c. group: 20.8 to 22.7 μg/
week; P = 0.014
Brunkhorst
et al. [47]
1502 rHuEPO BIW/TIW or
QW → DA QW or
Q2W, respectively
Multicentre, open
label
24 weeks (evaluation
weeks 21–24)
10–13 Change in mean dose on
conversion to DA:
i.v. group: decrease from 23.23
[95% CI 22.34–24.17] to
19.92 μg/ week [95% CI
19.02–20.87]
s.c. group: decrease from 22.95
[95% CI 21.90–24.06] to
21.61 μg/ week [95% CI
20.36–22.94]
Kessler et al. [48] 1008 rHuEPO BIW/TIW or
QW → DA QW or
Q2W, respectively
Multicentre
24 weeks (evaluation
weeks 21–24)
10–13 Change in median dose on
conversion to DA:
i.v. group: decrease from 27.3
to 22.3 μg/week
s.c. group: increase from 22.9
to 23.3 μg/week
Martinez Castelao
et al. [29]
826 rHuEPO BIW/TIW or
QW → DA QW or
Q2W, respectively
Multicentre
24 weeks (evaluation
weeks 21–24)
10–13 Change in mean dose on
conversion to DA:
i.v. group: −19.7% [95% CI
−24.9 to −14.2]
s.c. group: −4.7% [95% CI
−8.5 to −0.7]
CI, confidence interval; DA, darbepoetin alfa; EB, epoetin beta; i.v., intravenous; QW, once weekly; Q2W, every 2 weeks; REI, resistance index (weekly
dose per kg/haemoglobin level); rHuEPO, recombinant human erythropoietin (epoetin alfa or epoetin beta); s.c., subcutaneous; SD, standard deviation;
TIW, three times per week.
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In agreement with these data, results from a study by
Biggar and colleagues (discussed in the previous section
[41]) demonstrated that conversion of dialysis patients from
darbepoetin alfa to epoetin beta resulted in poorer control
of Hb levels at equimolar doses. Following the switch, the
mean Hb level decreased from 11.4 to 11.1 g/dL (P =
0.0016) and a 13% increase in the mean dose of epoetin
beta was necessary in order to maintain Hb ≥11 g/dL. These
findings are supported by further studies by Carrera et al.
[50] and Orazi et al. [51], which showed that converting
from darbepoetin alfa to epoetin alfa (Orazi et al.) or epoetin
beta (Carrera et al.) led to a decrease in the Hb level, with
an increase in epoetin dose.
Cost efficiency
In addition to the greater convenience that extended dos-
ing intervals bring to both patients and healthcare staff, the
use of longer acting agents such as darbepoetin alfa may
also yield significant increases in cost efficiency, based
on European clinical practice patterns. Studies in various
countries within Europe have demonstrated improvements
in cost and operational efficiency following a switch from
epoetin alfa to darbepoetin alfa therapy [52–55]. In addi-
tion, the MERCURIUS project, which is ongoing in 13
European countries, is expected to yield information on
how improvements could be made in ESA delivery and
utilization in hospitals throughout Europe [56].
In a UK study [52], 82 haemodialysis patients, stable on
s.c. epoetin alfa (administered BIW or TIW), for ≥6 months
prior to the study, were converted to i.v. darbepoetin alfa
QW or Q2W using the 200:1 initial dose conversion rule.
Following the switch, there was an increase in the mean Hb
concentration and an increase in the proportion of patients
meeting the EBPG Hb target range. There was also a signif-
icant decrease in the cost of ESA therapy (calculated from
costs published in the British National Formulary), which
more than offset a modest increase in the use of iron (from
£4.82/patient/week with epoetin alfa to £5.55/patient/week
with darbepoetin alfa). While the average cost of epoetin
alfa therapy was £62/patient/week, the cost for darbepoetin
alfa therapy was £48/patient/week—a 23% reduction per
patient resulting in a £75 000 yearly saving for the dialysis
unit. Furthermore, this figure does not take into account
further potential savings in drug preparation and adminis-
tration costs resulting from less frequent dosing with dar-
bepoetin alfa compared with epoetin alfa.
Similarly, in a Spanish study, 34 haemodialysis patients,
stable on i.v. rHuEPO QW, BIW or TIW, were switched to
i.v. darbepoetin alfa therapy (using the 200:1 dose conver-
sion factor) and dose adjustments were made to maintain
Hb concentrations close to 12 g/dL [53]. Treatment cost was
calculated from both the ESA drug acquisition cost and the
nursing cost related to drug administration. As shown in
Table 4, the mean ESA dose fell from 11 081 IU/week with
rHuEPO (equivalent to 55.4 μg/week darbepoetin alfa) to
35 μg/week after 6 months (P < 0.001), with a saving of
€146.22 per patient/month (cost reduction of 36.5%).
A third study conducted in Italy found that, for 61 evalu-
able patients switched from i.v. epoetin beta to i.v. darbepo-
Table 4. Increased cost efficiency on switching from epoetin alfa or
epoetin beta treatment to darbepoetin alfa therapy in Spanish haemodial-
ysis patients (n = 34)
rHuEPO Darbepoetin alfa
Baseline 1 month 3 months 6 months
Mean weekly 11 081 IU 50 μg∗ 39 μg∗ 35 μg∗
dose
Mean dose/ 44 324 IU 202 μg 157 μg 141 μg
patient/month
Mean drug cost/ €398.92 €360∗ €282.89∗ €254.12∗
patient/month
Mean nursing cost/ €1.98 €0.70 €0.49 €0.56
patient/month
Mean total cost/ €400.90 €360.7∗ €283.38∗ €254.68∗
patient/montha
Data from Ardevol et al. [53], reprinted with permission from Pharma
Publishing and Media Europe. Copyright 2006. All rights reserved.
rHuEPO, recombinant human erythropoietin.
aDrug plus nursing time costs.
∗P < 0.05 versus rHuEPO.
etin alfa QW, there were cost reductions of €570–710 per
patient per semester [54].
In view of these highly promising data, further studies
in large patient cohorts will be required to more clearly
determine the potential cost reductions associated with the
switch from older ESAs to darbepoetin alfa therapy in in-
dividual countries.
In addition to economic savings, the switch from epo-
etins to longer acting agents should also result in valuable
time savings for healthcare staff. A time and motion study
conducted at five dialysis centres in Sweden has provided
a useful indication of likely gains [55]. The time taken by
healthcare personnel to carry out various activities associ-
ated with the administration of epoetin alfa, epoetin beta
and darbepoetin alfa was recorded. Activities included re-
view of medical records to obtain the correct dose, retrieval
of drugs from the refrigerator and preparation for injection,
injection of the drug, drug ordering from the pharmacy, re-
ceipt and unpacking of drugs from the pharmacy and waste
management. A total of 342 patients receiving ESA treat-
ment at various dosing intervals (44% QW, 23% BIW, 24%
TIW and 9% at other dosing intervals) were included in
the study. The average time taken for ESA management per
dialysis session was 3 min (range 93–226 s). The average
time spent per patient per year was 4.7 h, and the average
time taken per centre per year was 319 h (range 55–586 h).
Time savings with Q2W dosing were estimated compared
to other dosing intervals. With Q2W dosing the estimated
average time spent on ESA management per patient per year
was 1.3 h—a saving of 3.4 h per year compared with the
current dosing intervals. However, large variations in time
spent were observed, depending on the size of the dialysis
centre. In addition, the estimated average time per centre
per year was 89 h (range 23–133 h)—a saving of 230 h
compared with the current dosing intervals. While fur-
ther large-scale international studies are required to more
fully assess the impact of extended ESA dosing intervals
on healthcare resource utilization in the management of
anaemic CKD patients, these data suggest that the more
i16 F. Carrera and M. Burnier
Fig. 3. The MERCURIUS study: overall and by country cost per patient
per year∗ after switching from rHuEPO TIW to darbepoetin alfa Q2W.
(A) Pharmacy labour costs; (B) dialysis unit materials and labour costs
[56].
widespread use of longer acting agents in certain situations
could provide economic benefits.
The MERCURIUS project, now underway in 13
European countries, should provide a clearer picture of the
benefits of extended ESA dosing intervals in CKD pa-
tients undergoing haemodialysis. This study, taking a much
broader view than the Swedish time analysis, aims to char-
acterize the whole process of ESA delivery at each study
centre, from initial drug ordering to the disposal of waste
product. MERCURIUS will also evaluate the impact of
changing from current ESA dosing frequencies to Q2W
dosing with darbepoetin alfa. When available, its find-
ings should yield useful recommendations on how hospi-
tals can improve operational efficiency, including improved
ESA utilization. Preliminary data collected by Burnier
et al. [56] from eight centres in five European countries
have estimated mean costs for various activities associated
with ESA administration. By using a fixed Q2W dosing
schedule, Burnier et al. estimated a mean reduction in cost
of 25% in pharmacy labour and 64% in dialysis unit labour.
Figure 3 shows the cost per patient per year overall and in-
dividually in five countries; pharmacy labour costs, as well
as dialysis unit materials and labour costs, were reduced
after switching to darbepoetin alfa Q2W from epoetin TIW.
Other potential benefits of less frequent dosing include less
waste from packaging and cooling elements for transport,
reduced risk of needle stick injuries for medical staff and
reduced potential for incorrect dosing. It is hoped that the
results of MERCURIUS will allow the setting of bench-
marks and the sharing of best practice between European
dialysis centres.
Acknowledgement. Medical writing support was provided by Jane Black-
burn, PhD, Gardiner-Caldwell Communications.
Conflict of interest statement. This manuscript was sponsored by Amgen
(Europe) GmbH. F.C. is a scientific consultant for Amgen (Europe) and
Vifor (International). M.B. has received research grants from Amgen and
has been a speaker for Amgen.
References
1. Bradbury BD, Fissell RB, Albert JM et al. Predictors of early mortality
among incident US hemodialysis patients in the Dialysis Outcomes
and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007;
2: 89–99
2. Foley RN, Parfrey PS, Harnett JS et al. The impact of anemia on
cardiomyopathy, morbidity and mortality in end-stage renal disease.
Am J Kidney Dis 1996; 28: 53–61
3. Rao M, Pereira BJ. Optimal anemia management reduces cardiovas-
cular morbidity, mortality, and costs in chronic kidney disease.Kidney
Int 2005; 68: 1432–1438
4. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis pa-
tients of five European countries: association with morbidity and mor-
tality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Nephrol Dial Transplant 2004; 19: 121–132
5. Regidor DL, Kopple JS, Lovesdy CP et al. Associations between
changes in hemoglobin and administered erythropoiesis-stimulating
agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;
17: 1181–1191
6. Locatelli F, Aljama P, Barany P et al. Revised European best practice
guidelines for the management of anaemia in patients with chronic
renal failure. Nephrol Dial Transplant 2004; 19: ii1–ii47
7. KDOQI; National Kidney Foundation. KDOQI Clinical practice
guidelines and clinical practice recommendations for anaemia in
chronic kidney disease. Am J Kidney Dis 2006; 47: S11–S145
8. Drueke TB, Locatelli F, Clyne N et al. Normalization of haemoglobin
level in patients with chronic kidney disease and anemia. N Engl J
Med 2006; 335: 2071–2084
9. Singh AK, Szczech L, Tang KL et al. Correction of anaemia with
epoetin alfa in chronic kidney disease. N Engl J Med 2006; 335:
2085–2098
10. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target
haemoglobin concentrations in anaemia patients with chronic kid-
ney disease treated with erythropoietin: a meta-analysis. Lancet 2007;
369: 381–388
11. Eprex R© SmPC, Janssen-Cilag, 2008. http://emc.medicines.org.uk/
emc/assets/c/html/displaydoc.asp?documentid=889 (11 September
2008, date last accessed)
12. Aranesp R© SmPC, Amgen, 2008. http://emc.medicines.org.uk/emc/
assets/c/html/displaydoc.asp?documentid=4981 (11 September
2008, date last accessed)
13. NeoRecormon R© SmPC, Roche, 2008. http://emc.medicines.org.uk/
emc/assets/c/html/displaydoc.asp?documentid=7747 (11 September
2008, date last accessed)
14. MIRCERA R© SmPC, Roche, 2008. http://emc.medicines.org.uk/emc/
assets/c/html/displaydoc.asp?documentid=19960 (11 September
2008, date last accessed)
15. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the
CHOIR trial epoetin-α dose and achieved haemoglobin outcomes.
Kidney Int 2008; 74: 791–798
16. Mix TC, Brenner RM, Cooper ME et al. Rationale—Trial to Reduce
Cardiovascular Events with Aranesp Therapy (TREAT): evolving the
management of cardiovascular risk in patients with chronic kidney
disease. Am Heart J 2005; 149: 408–413
17. Carrera F, Macdougall IC. Hemoglobin targets: the jury is still out.
Clin Nephrol 2008; 69: 8–9
18. Abseamed R© SmPC, Medice Arzneimittel Pu¨tter, 2008. http://www.
emea.europa.eu/humandocs/PDFs/EPAR/abseamed/H-727-PI-en.pdf
(11 September 2008, date last accessed)
19. Binocrit R© SmPC, Sandoz, 2008. http://www.emea.europa.eu/
humandocs/PDFs/EPAR/binocrit/H-725-PI-en.pdf (11 September
2008, date last accessed)
20. Epoetin alfa HEXAL R© SmPC, HEXAL Biotech Forschungs
GmbH, 2008. http://www.emea.europa.eu/humandocs/PDFs/EPAR/
epoetinalfahexal/H-726-PI-en.pdf (11 September 2008, date last ac-
cessed)
21. Hertel J, Locay H, Scarlata D et al. Darbepoetin alfa administered
every other week maintains haemoglobin levels over 52 weeks in
patients with chronic kidney disease converting from once-weekly
Use of darbepoetin alfa in anaemia of CKD i17
recombinant human erythropoietin: results from Simplify the Treat-
ment of Anemia with Aranesp (STAAR).AmJNephrol 2006; 26: 149–
156
22. Hertel JE, Locay HR, Scarlata DS et al. Darbepoetin alfa adminis-
tration to achieve and maintain target haemoglobin levels for 1 year
in patients with chronic kidney disease. Mayo Clin Proc 2006; 81:
1188–1194
23. Toto RD, Pichette V, Navarro J et al. Darbepoetin alfa effectively
treats anemia in patients with chronic kidney disease with de novo
every-other-week administration. Am J Nephrol 2004; 24: 453–460
24. Ling B, Walczyk M, Agarwal A et al. Darbepoetin alfa administered
once monthly maintains haemoglobin concentrations in patients with
chronic kidney disease. Clin Nephrol 2005; 63: 327–334
25. Agarwal A, Silver MR, Walczyk M et al. Once-monthly darbepoetin
alfa for maintaining hemoglobin levels in older patients with chronic
kidney disease. J Am Med Dir Ass 2007; 8: 83–90
26. Agarwal A, Silver M, Reed J et al. An open-label study of darbepoetin
alfa administered once monthly for the maintenance of haemoglobin
concentrations in patients with chronic kidney disease not receiving
dialysis. J Int Med 2006; 260: 577–585
27. Hoggard J, Crouch T, McMurray S et al. Preference for monthly
darbepoetin alfa dosing in patients with chronic kidney disease not
receiving dialysis. Curr Med Res Opin 2006; 22: 2023–2030
28. Disney A, Jersey P, Kirkland G et al. Darbepoetin alfa adminis-
tered monthly maintains haemoglobin concentrations in patients with
chronic kidney disease not receiving dialysis: a multicentre, open-
label, Australian study. Nephrology 2007; 12: 95–101
29. Martinez Castelao A, Reyes A, Valdes F et al. Multicenter study of
darbepoetin alfa in the treatment of anemia secondary to chronic renal
insufficiency on dialysis. Nefrologia 2003; 23: 114–124
30. Del Vecchio L, Villa G, Carraro G et al. Italian study on the treat-
ment of anaemia in chronic dialysis patients switched over to less
frequent doses of darbepoetin from human recombinant erythropoi-
etin (rHuEPO). G Ital Nefrol 2004; 21: 259–266
31. Vanrenterghem Y, Ba´ra´ny P, Mann JF et al. Randomized trial of
darbepoetin alfa for treatment of renal anemia at a reduced dose
frequency compared with rHuEPO in dialysis patients. Kidney Int
2002; 62: 2167–2175
32. Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. The efficacy
of intravenous darbepoetin alfa administered once every 2 weeks in
chronic kidney disease patients on haemodialysis.Nephrol Dial Trans-
plant 2006; 21: 2846–2850
33. Mann J, Kessler M, Villa G et al. Darbepoetin alfa once every 2 weeks
for treatment of anemia in dialysis patients: a combined analysis of
eight multicenter trials. Clin Nephrol 2007; 67: 140–148
34. Provenzano R, Besarab A, Macdougall IC et al. The continuous ery-
thropoietin receptor activator (C.E.R.A.) corrects anaemia at extended
administration intervals in patients with chronic kidney disease not on
dialysis: results of a phase II study. Clin Nephrol 2007; 67: 306–317
35. Sulowicz W, Locatelli F, Ryckelynck JP et al. Once-monthly sub-
cutaneous C.E.R.A. maintains stable hemoglobin control in patients
with chronic kidney disease on dialysis and converted directly from
epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2:
637–646
36. Levin NW, Fishbane S, Valdes Canedo F et al. Intravenous methoxy
polyethylene glycol-epoetin beta for haemoglobin control in patients
with chronic kidney disease who are on dialysis: a randomised non-
inferiority trial (MAXIMA). Lancet 2007; 370: 1415–1421
37. Macdougall IC, Walker R, Provenzano R et al. C.E.R.A. corrects
anemia in patients with chronic kidney disease not on dialysis: results
of a randomized clinical trial.Clin J Am SocNephrol 2008; 3: 337–347
38. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with
intravenous epoetin in patients receiving hemodialysis: Department
of Veterans Affairs Cooperative Study Group on Erythropoietin in
Hemodialysis Patients. N Engl J Med 1998; 339: 578–583
39. Locatelli F, Canaud B, Giacardy F et al. Treatment of anaemia in
dialysis patients with unit dosing of darbepoetin alfa at a reduced dose
frequency relative to recombinant human erythropoietin (rHuEpo).
Nephrol Dial Transplant 2003; 18: 362–369
40. Rutkowski B, Bitterova Z, Ferenczi S et al. Effectiveness of convert-
ing from itravenous (iv) or subcutaneous (sc) recombinant human
erythropoietin (rHuEPO) to iv darbepoetin alfa (DA) in end stage
renal disease (ESRD) patients (Pts) on hemodialysis (HD) [abstract].
Presented atAmerican Society of Nephrology Annual Congress, 14–19
November 2006, San Diego, CA, USA
41. Biggar P, Ketteler M, Hennemann H et al. Switch of ESA therapy from
darbepoetin-α to epoetin-β in hemodialysis patients: a single-center
experience. Clin Nephrol 2008; 68: 185–192
42. Tolman C, Richardson D, Bartlett C et al. Structured conversion from
thrice weekly to weekly erythropoietic regimens using a computer-
ized decision-support system: a randomized clinical study. J Am Soc
Nephrol 2005; 16: 1463–1470
43. Molina M, Garcı´a Herna´ndez MA, Navarro MJ et al. Change of
EPO treatment from subcutaneous epoetin to intravenous epoetin or
darbepoetin alfa. Nefrologia 2004; 24: 564–571
44. Ho¨rl WH, Holzer H, Mayer GJ for the Osterreichische Aranesp Stu-
diengruppe. Treatment of renal anemia with darbepoetin alfa: results
of an Austrian multicenter study. Wien Klin Wochenschr 2002; 114:
967–971
45. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled
trial of darbepoetin alfa for the treatment of anemia in hemodialysis
patients. Am J Kidney Dis 2002; 40: 110–118
46. Bock HA, Hirt-Minkowski P, Brunisholz M et al. Darbepoetin alpha
in lower-than-equimolar doses maintains haemoglobin levels in stable
haemodialysis patients converting from epoetin alpha/beta. Nephrol
Dial Transplant 2008; 23: 301–308
47. Brunkhorst R, Bommer J, Braun J et al. Darbepoetin alfa effectively
maintains haemoglobin concentrations at extended dose intervals rela-
tive to intravenous or subcutaneous recombinant human erythropoietin
in dialysis patients. Nephrol Dial Transplant 2004; 19: 1224–1230
48. Kessler M, Hannedouche T, Fitte H et al. For the Groupe de l’etude
NESP. Darbepoetin-alfa treatment of anemia secondary to chronic
renal failure in dialysis patients: results of a French multicenter study.
Nephrol Ther 2006; 2: 191–199
49. Torres PU, Maetzel A. Dose efficiency of Aranesp R©(darbepoetin
alfa) compared with epoetin alfa/beta in dialysis patients—a meta
analysis. Presented at 44th ERA-EDTA Congress, 21–24 June 2007,
Barcelona, Spain
50. Carrera F, Neto R, Bridges I et al. Lower mean haemoglobin (Hb) lev-
els and higher erythropoiesis-stimulating agent (ESA) dose require-
ments in chronic kidney disease (CKD) hemodialysis (HD) patients
(Pts) switched from Aranesp (darbepoetin alfa [DA]) QW iv to epoetin
beta (EB) iv administration [abstract]. Presented at American Society
of Nephrology Annual Congress, 31 October–5 November 2007, San
Francisco, CA, USA
51. Orazi E. Switch from darbepoetin-α to epoetin-α: cost and efficiency
comparison for haemodialytic patients over one year follow-up in a
single centre (Italian). G Ital Nefrol 2008; 25: 223–226
52. Summers S, Winnett G, Matijevic A et al. An audit comparing sub-
cutaneous epoetin alfa to intravenous darbepoetin alfa in chronic
hemodialysis patients. Dial Transplant 2005; 34: 358–362
53. Ardevol M, Fontsere´ N, Casals M et al. A feasibility cost-analysis
study of recombinant human erythropoietin and darbepoetin alfa in
ambulatory haemodialysis patients during current clinical practice.
Eur J Hosp Pharm Sci 2006; 12: 47–51
54. Biamino E, Giotta N, Caligaris F et al. Cost-efficacy analysis of dar-
bepoetin alfa after switch from epoetin beta in hemodialysis patients:
a retrospective monocentric study [abstract PUB284]. Presented at
American Society of Nephrology Annual Congress, 27 October–
1 November 2004, St Louis, MO, USA
55. Wikstro¨m B, Gutierrez A, Jacobson S et al. Time gain with every other
week administration of erythropoiesis-stimulating agents to patients
in haemodialysis [abstract SP451]. Nephrol Dial Transplant 2006; 21:
iv166–iv167
56. Burnier M, Demay J, Tanghe A. Less frequent dosing of
erythropoiesis-stimulating agents may result in cost savings in
European dialysis centers [abstract]. J Am Soc Nephrol 2007; 18:
83A
Received for publication: 19.9.08
Accepted in revised form: 21.10.08
